Impact of Delayed Diagnosis and Treatment in Clinically Isolated Syndrome and Multiple Sclerosis

ABSTRACT Multiple sclerosis (MS) is a progressive inflammatory disease with several possible clinical courses; before the development of definite MS, some patients may have clinically isolated syndrome (CIS), which is a single attack of neurological symptoms caused by inflammation or demyelination. Disease-modifying treatments (DMTs) have been extensively used for the management of MS, resulting in improvements in the clinical presentation and decreases in MS-associated neurological damage. Earlier initiation of DMT in the course of MS is associated with better outcomes. For patients with CIS, initiation of interferon-beta or glatiramer acetate treatment after an initial clinical event indicative of MS has been associated with delays in the progression to clinically definite MS as well as improvements in measures of neurological damage via magnetic resonance imaging. The initiation of treatment for patients with CIS should be considered, and nurses play a vital role in educating patients about the risks of conversion to MS and the benefits of early DMT.

[1]  R. Kinkel,et al.  Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. , 2012, Archives of neurology.

[2]  H. Panitch,et al.  Early stage and long term treatment of multiple sclerosis with interferon-β , 2009, Biologics : targets & therapy.

[3]  J. Ranjeva,et al.  Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  K. Hawker,et al.  Progressive multiple sclerosis: characteristics and management. , 2011, Neurologic clinics.

[5]  Ludwig Kappos,et al.  Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial , 2012, The Lancet Neurology.

[6]  O. Gout,et al.  Prior suggestive symptoms in one-third of patients consulting for a “first” demyelinating event , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  R. Marrie,et al.  Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS , 2010, Current medical research and opinion.

[8]  E. Mowry,et al.  Clinical predictors of early second event in patients with clinically isolated syndrome , 2009, Journal of Neurology.

[9]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[10]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[11]  M. Hutchinson,et al.  Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice , 2011, Multiple sclerosis.

[12]  M. Ron,et al.  Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  B. Brochet,et al.  Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[15]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[16]  P. Rieckmann.  Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. , 2005, International MS journal.

[17]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[18]  Amy Perrin Ross,et al.  Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis , 2010, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[19]  Helen Tremlett,et al.  Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts , 2010, Journal of the Neurological Sciences.

[20]  M. Tintoré,et al.  Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. , 2008, The Cochrane database of systematic reviews.

[21]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[22]  Anthony Traboulsee,et al.  Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  D. Goodin,et al.  Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode , 2009, Multiple sclerosis.

[24]  M. Kremenchutzky,et al.  Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria , 2009, Multiple sclerosis.

[25]  T. Scott,et al.  Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later , 2010, Journal of the Neurological Sciences.

[26]  C. L. Callahan,et al.  The quality of life. , 1970, Nursing outlook.

[27]  M. Filippo,et al.  Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  P. Coyle.  Early treatment of multiple sclerosis to prevent neurologic damage , 2008, Neurology.

[29]  B. Thrower.  Clinically isolated syndromes , 2007, Neurology.

[30]  M. Filippi,et al.  Inflammatory demyelination and neurodegeneration in early multiple sclerosis , 2007, Journal of the Neurological Sciences.

[31]  G. Comi.  Clinically isolated syndrome: the rationale for early treatment , 2008, Nature Clinical Practice Neurology.

[32]  D. Goodin.  IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event , 2006, Neurology.

[33]  C. Constantinescu,et al.  Current and future disease‐modifying therapies in multiple sclerosis , 2010, International journal of clinical practice.

[34]  N. Sicotte.  Magnetic resonance imaging in multiple sclerosis: the role of conventional imaging. , 2011, Neurologic clinics.

[35]  P. O'Connor.  The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. , 2003, Clinical therapeutics.

[36]  F. Barkhof,et al.  Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[37]  J. Fischer,et al.  Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis , 2009, European journal of neurology.

[38]  F. Barkhof,et al.  Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b , 2008, Journal of Neurology.

[39]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[40]  S. Galetta,et al.  US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis , 2005, CNS drugs.

[41]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[42]  H. Weiner,et al.  Cognitive deterioration in patients with early multiple sclerosis: a 5-year study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[43]  B. Hurwitz.  The diagnosis of multiple sclerosis and the clinical subtypes , 2009, Annals of Indian Academy of Neurology.

[44]  U. Webb.  Early Interferon Beta Treatment in Multiple Sclerosis: Nursing Care Implications of the BENEFIT Study , 2008, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[45]  Hirofumi Ochi,et al.  [Cognitive impairment in multiple sclerosis]. , 2014, Brain and nerve = Shinkei kenkyu no shinpo.

[46]  S. Fereshtehnejad,et al.  The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis , 2007, Clinical Neurology and Neurosurgery.

[47]  A. Bar-Or,et al.  Beta interferons in clinically isolated syndromes: a meta-analysis. , 2008, Arquivos de neuro-psiquiatria.

[48]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[49]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.

[50]  M. Sahraian,et al.  Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event , 2007, Acta neurologica Scandinavica.

[51]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[52]  L. Durelli,et al.  The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug A critical evaluation based upon evidence based parameters and published systematic reviews , 2008, Clinical Neurology and Neurosurgery.

[53]  B. Hemmer,et al.  Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. , 2012, Current pharmaceutical design.

[54]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[55]  À. Rovira,et al.  Baseline MRI predicts future attacks and disability in clinically isolated syndromes , 2006, Neurology.

[56]  Peter A Calabresi,et al.  Diagnosis and management of multiple sclerosis. , 2004, American family physician.

[57]  A. Kyritsis,et al.  Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment , 2008, Therapeutics and clinical risk management.

[58]  G. Izquierdo,et al.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study) , 2010, Journal of Neurology.

[59]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.